Vinflunine
- Generic Name
- Vinflunine
- Brand Names
- Javlor
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54F2N4O8
- CAS Number
- 162652-95-1
- Unique Ingredient Identifier
- 5BF646324K
- Background
Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis . Vinflunine is a microtubule inhibit...
- Indication
For use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy .
- Associated Conditions
- Transitional Cell Carcinoma of the Urothelial Tract, Metastatic Transitional Cell Carcinoma of the Urothelial Tract
- Associated Therapies
- -
Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 696
- Registration Number
- NCT04527991
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of California Irvine (UCIMC), Orange, California, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- Conditions
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT03474107
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇧🇪Site BE32013, Brussels, Belgium
🇧🇪Site BE32001, Gent, Belgium
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- Conditions
- Interventions
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 629
- Registration Number
- NCT03390504
- Locations
- 🇨🇦
Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Ligartis GmbH
- Registration Number
- NCT02845050
- Locations
- 🇩🇪
Dept. Urology, University Hospital Marburg, Marburg/ Lahn, Baldingerstraße, Germany
🇩🇪Dept. Urology, University Hospital Tübingen, Tübingen, Hoppe-Seyler-Straße 3, Germany
A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
- Conditions
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Dr Anders Ullén
- Target Recruit Count
- 62
- Registration Number
- NCT02665039
- Locations
- 🇩🇰
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
🇸🇪Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 459
- Registration Number
- NCT02347332
- Locations
- 🇫🇷
Institut de Recherche Pierre Fabre, Toulouse, France
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
- Conditions
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 931
- Registration Number
- NCT02302807
- Locations
- 🇷🇸
Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
🇬🇧Barts and The London, London, United Kingdom
🇨🇦Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
- Conditions
- Interventions
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 542
- Registration Number
- NCT02256436
A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 22
- Registration Number
- NCT02057913
- Locations
- 🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom
🇬🇧Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, Merseyside, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, Greater London, United Kingdom
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 112
- Registration Number
- NCT01953003
- Locations
- 🇸🇬
Gleneagles Hospital, Singapore, Singapore
🇸🇬NUH, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.